Neuren Pharmaceuticals in Australia sets primary goals for Phase III trial of NNZ-2591 drug in treating Phelan-McDermid syndrome (PMS) for 13 weeks, based on FDA meeting. Trial endpoints focus on communication and PMS symptoms improvement, following positive Phase II results.